<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798963</url>
  </required_header>
  <id_info>
    <org_study_id>MACT-PN 2021</org_study_id>
    <nct_id>NCT04798963</nct_id>
  </id_info>
  <brief_title>The Evaluation of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy</brief_title>
  <official_title>3D Assessment of Functional Parenchymal Volume and Split Renal Function Before and After Partial Nephrectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare pre- and postoperative 3D renal function results of patients who&#xD;
      underwent on-clamp and off-clamp partial nephrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2021</start_date>
  <completion_date type="Anticipated">March 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GFR after the surgery</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rate (Clavien-Dindo)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>On-clamp partial nephrectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are assigned to on-clamp partial nephrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Off-clamp partial nephrectomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who are assigned to off-clamp partial nephrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>On-clamp partial nephrectomy</intervention_name>
    <description>Partial nephrectomy will performed with renal artery clamping (less than or equal to 25 minutes)</description>
    <arm_group_label>On-clamp partial nephrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Off-clamp partial nephrectomy</intervention_name>
    <description>Partial nephrectomy will performed without renal artery clamping</description>
    <arm_group_label>Off-clamp partial nephrectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Men and women &gt;18 years; 2. Diagnosis of unilateral renal cell carcinoma (stage&#xD;
        T1-T3aN0M0); 3. Planned surgery: retroperitoneoscopic/laparoscopic/robotic partial&#xD;
        nephrectomy; 4. Patients with CT of the kidneys with contrast enhancement performed&#xD;
        according to the required protocol.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years old or ASA&gt; 3;&#xD;
&#xD;
          2. Solitary kidney;&#xD;
&#xD;
          3. Bilateral kidney&#xD;
&#xD;
          4. The presence of concomitant systemic pathology (DM, AH), as well as kidney disease&#xD;
             (glomerulonephritis), which can change the state of the renal parenchyma;&#xD;
&#xD;
          5. Obstructive nephropathy&#xD;
&#xD;
          6. Systemic intake of nephrotoxic drugs;&#xD;
&#xD;
          7. Pregnancy. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dmitry Fiev, M.D., Ph.D.</last_name>
    <phone>+79265690949</phone>
    <email>fiev@mail.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitry Enikeev, M.D., Ph.D.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sechenov University.</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Enikeev, MD</last_name>
      <phone>+7 925 517 79 26</phone>
      <email>enikeev-dv@1msmu.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Dmitry Enikeev, MD, PhD</investigator_full_name>
    <investigator_title>Deputy Director for Research</investigator_title>
  </responsible_party>
  <keyword>kidney cancer</keyword>
  <keyword>partial nephrectomy</keyword>
  <keyword>split renal function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

